PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.83%
Revenue growth at 50-75% of META's 12.29%. Martin Whitman would worry about competitiveness or product relevance.
8.75%
Gross profit growth at 50-75% of META's 12.33%. Martin Whitman would question if cost structure or brand is lagging.
7.70%
EBIT growth 50-75% of META's 10.27%. Martin Whitman would suspect suboptimal resource allocation.
7.70%
Operating income growth under 50% of META's 16.44%. Michael Burry would be concerned about deeper cost or sales issues.
17.77%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
21.43%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
21.43%
Diluted EPS growth above 1.5x META's 11.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.08%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-0.03%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
38.42%
OCF growth above 1.5x META's 6.39%. David Dodd would confirm a clear edge in underlying cash generation.
32.32%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
3967.29%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
298.59%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
68.19%
3Y revenue/share CAGR at 75-90% of META's 77.04%. Bill Ackman would expect new product strategies to close the gap.
No Data
No Data available this quarter, please select a different quarter.
285.33%
Below 50% of META's 653.02%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
72.67%
3Y OCF/share CAGR at 50-75% of META's 125.05%. Martin Whitman would suspect weaker recent execution or product competitiveness.
5182.32%
Net income/share CAGR above 1.5x META's 2770.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
390.90%
5Y net income/share CAGR 1.25-1.5x META's 304.58%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
97.82%
3Y net income/share CAGR 50-75% of META's 194.47%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
325.12%
5Y equity/share CAGR above 1.5x META's 101.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
101.01%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.47%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
109.09%
Inventory growth of 109.09% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
11.03%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.50%
1.25-1.5x META's 5.80%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
10.69%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
9.45%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.